XML 77 R57.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Sep. 26, 2020 | Sep. 28, 2019 | Mar. 30, 2019 | Sep. 26, 2020 | Sep. 28, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Jun. 27, 2020 | Jun. 29, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Transfers among level 1, 2, and 3 | $ 0.0 |  |  | $ 0.0 |  |  | $ 0.0 |  |  |
Income recognized from change is asset | 22.2 | $ 2.6 |  | 25.9 | $ 18.5 |  |  |  |  |
Royalty Pharma Contingent Milestone Payments |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales included in calculation for milestone payment |  |  |  |  |  |  | 0.0 | $ 337.5 |  |
Payments received |  |  | $ 250.0 |  |  |  |  |  |  |
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3 |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Increase (decrease) in fair value of milestone payment | 22.2 | 2.6 |  | 25.9 | 18.5 |  |  |  |  |
Estimated fair valued contingent milestone payment | 121.2 | 91.7 |  | 121.2 | 91.7 |  | $ 95.3 | $ 323.2 | $ 99.0 | $ 89.1
Payments received | 0.0 | $ 0.0 |  | 0.0 | $ 250.0 |  |  |  |  |
Royalty Pharma 2020 Contingent Milestone Payments | Measured on a recurring basis | Level 3 |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Estimated fair valued contingent milestone payment | $ 121.2 |  |  | $ 121.2 |  |  |  |  |  |
Royalty Pharma |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Volatility | 30.00% | 30.00% |  |  |  |  |  |  |  |
Rate of return | 6.84% | 7.99% |  |  |  |  |  |  |  |
Scenario, Forecast |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Royalty Pharma contingent payment sales threshold |  |  |  |  |  | $ 400.0 |  |  |  |
Scenario, Forecast | Royalty Pharma Contingent Milestone Payments |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Royalty Pharma contingent payment sales threshold |  |  |  |  |  | 400.0 |  |  |  |
Net sales threshold to trigger milestone payment |  |  |  |  |  | 351.0 |  |  |  |
Income recognized from change is asset |  |  |  |  |  | $ 278.8 |  |  |  |
Discounted Cash Flow | Contingent Consideration | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration payments: sales-based milestones (percent) |  |  |  | 26.00% |  |  |  |  |  |
RX | Discounted Cash Flow | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, fair value (percent) | 10.30% |  |  |  |  |  |  |  |  |
RX | Discounted Cash Flow | Measurement Input, Long-term Growth Rate |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Reporting unit, fair value (percent) | 0.00% |  |  |  |  |  |  |  |  |
Minimum | RX | Discounted Cash Flow |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Blended jurisdictional tax rates (percent) | 19.10% |  |  |  |  |  |  |  |  |
Maximum | RX | Discounted Cash Flow |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |
Blended jurisdictional tax rates (percent) | 21.70% |  |  |  |  |  |  |  |  |

X
- Definition Asset, Adjusted Fair Value if Sales Threshold Met + References No definition available. + Details
Name: | prgo_AssetAdjustedFairValueifSalesThresholdMet
Namespace Prefix: | prgo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Blended Jurisdictional Tax Rates, Percent + References No definition available. + Details
Name: | prgo_BlendedJurisdictionalTaxRatesPercent
Namespace Prefix: | prgo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Consideration Payments, Sales-based Milestones, Percent + References No definition available. + Details
Name: | prgo_ContingentConsiderationPaymentsSalesbasedMilestonesPercent
Namespace Prefix: | prgo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount + References No definition available. + Details
Name: | prgo_FairValueAssetsLevel1Level2Level3TransfersAmount
Namespace Prefix: | prgo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair Value Assumption, Volatility + References No definition available. + Details
Name: | prgo_FairValueAssumptionVolatility
Namespace Prefix: | prgo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Assumptions, Rate of Return + References No definition available. + Details
Name: | prgo_FairValueAssumptionsRateofReturn
Namespace Prefix: | prgo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Net Sales Included in Calculation For Milestone Payment + References No definition available. + Details
Name: | prgo_NetSalesIncludedinCalculationForMilestonePayment
Namespace Prefix: | prgo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Net Sales Threshold For Milestone Payment + References No definition available. + Details
Name: | prgo_NetSalesThresholdForMilestonePayment
Namespace Prefix: | prgo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reporting Unit, Fair Value, Percent + References No definition available. + Details
Name: | prgo_ReportingUnitFairValuePercent
Namespace Prefix: | prgo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612 + Details
Name: | us-gaap_FairValueOptionChangesInFairValueGainLoss1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=prgo_RoyaltyPharmaContingentMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=prgo_RoyaltyPharma2020ContingentMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=prgo_RoyaltyPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=prgo_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=prgo_RXPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputLongTermRevenueGrowthRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |